# US 2023/0265486 A1 · Methods for selective cell-free nucleic acid analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265486 A1
- Document ID: US20230265486A1
- Status: Published application
- Kind: A1
- Application number: 18/170,265
- Filed: 2023-02-16
- Published: 2023-08-24
- Earliest claimed: 2020-08-19
- Assignees: Accuragen Holdings Limited
- Applicants: AccuraGen Holdings Limited
- Inventors: Li WENG; Malek FAHAM; Tobias WITTKOP
- Web page: https://patentgrep.com/patent/US20230265486A1

## CPC

- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are methods for processing a plurality of nucleic acid molecules derived from a cell-free biological sample, comprising bringing said plurality of nucleic acid molecules or derivatives thereof in contact with a plurality of binding agents, to provide a first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents and a second subset of said plurality of nucleic acid molecules; separating said first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents from said second subset of said plurality of nucleic acid molecules; circularizing a nucleic acid molecule derived from said first subset of said plurality of nucleic acid molecules to obtain a circularized nucleic acid molecule; and identifying said circularized nucleic acid molecule or derivative thereof.

## Claims

### Claim at position 1

-36. (canceled)

### Claim 37

A method for processing a plurality of nucleic acid molecules derived from a cell-free biological sample, comprising (a) determining a methylation state fora nucleic acid molecule of said plurality of nucleic acid molecules; (b) determining a size for said nucleic acid molecule of said plurality of nucleic acid molecules; and (c) processing (i) said methylation state for said nucleic acid molecule of said plurality of nucleic acid molecules against a first database, and (ii) said size for said nucleic acid molecule of said plurality of nucleic acid molecules against a second database, to identify an association of said methylation state and of said size with at least a disease.

### Claim 38 (depends on 37)

The method of claim 37, wherein determining said methylation state comprises sequencing said nucleic acid molecule of said plurality of nucleic acid molecules.

### Claim 39

(canceled)

### Claim 40 (depends on 37)

The method of claim 37, wherein determining said methylation state comprises contacting said nucleic acid molecule to a binding agent that binds specifically to methylated nucleic acids or a derivative thereof.

### Claim 41

The method of claim to 37, wherein determining said methylation state comprises (a) bringing said plurality of nucleic acid molecules in contact with a plurality of binding agents, to provide a first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents and a second subset of said plurality of nucleic acid molecules; (b) separating said first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents from said second subset of said plurality of nucleic acid molecules; (c) subsequent to (b), circularizing a nucleic acid molecule derived from said first subset of said plurality of nucleic acid molecules to obtain a circularized nucleic acid molecule; and (d) identifying said circularized nucleic acid molecule or derivative thereof.

### Claim 42 (depends on 37)

The method of claim 37, wherein said binding agent comprises an antibody, or fragment thereof.

### Claim 43 (depends on 37)

The method of any one of claim 37, wherein said binding agent comprises a polypeptide or a nucleic acid.

### Claim at position 9 (depends on 43)

44 The method of claim 43, wherein said polypeptide comprises streptavidin.

### Claim 45 (depends on 37)

The method of any one of claim 37, wherein said plurality of nucleic acid molecules comprise a deoxyribonucleic acid (DNA) molecule or a ribonucleic acid (RNA) molecule.

### Claim 46 (depends on 41)

The method of claim 41, wherein circularizing comprises ligating a 5′ end and a 3′ end of said nucleic acid molecule to one another.

### Claim 47 (depends on 41)

The method of claim 41, wherein circularizing comprises coupling an adapter to a 3′ end, a 5′ end, or both a 5′ end and a 3′ end of said nucleic acid molecule.

### Claim 48 (depends on 41)

The method of claim 41, further comprising subjecting said circularized nucleic acid molecule to nucleic acid amplification to generate a plurality of amplification products of said circularized nucleic acid molecule, wherein (d) comprises identifying said plurality of nucleic acid amplification products.

### Claim at position 14

-50. (canceled)

### Claim 51 (depends on 48)

The method of claim 48, wherein said nucleic acid amplification comprises contacting said circularized nucleic acid molecule to an amplification reaction mixture comprising random primers.

### Claim 52 (depends on 48)

The method of claim 48, wherein said nucleic acid amplification comprises contacting said circularized nucleic acid molecule to an amplification reaction mixture comprising one or more primers, each of which specifically hybridizes to a different target sequence via sequence complementarity.

### Claim at position 17

-55 (canceled)

### Claim 56 (depends on 37)

The method of claim 37, wherein said cell-free biological sample comprises a bodily fluid comprising urine, saliva, blood, serum, plasma, tears, sputum, cerebrospinal fluid, synovial fluid, mucus, bile, semen, lymph, amniotic fluid, menstrual fluid, or combinations thereof.

### Claim 57

(canceled)

### Claim at position 20 (depends on 37)

58 The method of claim 37, further comprising processing said methylation state and against a plurality of reference methylation states and processing said size against a plurality of reference sizes to identify said methylation state as corresponding to at least a subset of said plurality of reference methylation states and said size as corresponding to at least a subset of said reference sizes, thereby determining that a subject has or is at risk of having a disease.

### Claim 59 (depends on 58)

The method of claim 58, wherein said disease is cancer selected from the group consisting of colon cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, hepatocellular carcinoma, liver cancer, skin cancer, malignant melanoma endometrial cancer, esophageal cancer, gastric cancer, ovarian cancer, pancreatic cancer, brain cancer, leukemia, lymphoma, and myeloma.

### Claim 60

(canceled)

### Claim 61 (depends on 58)

The method of claim 58, further comprising using said methylation state and said size identified to output an electronic report indicating that said subject has or is at risk of having a disease.

### Claim 62 (depends on 58)

The method of claim 58, further comprising using said methylation state and said size identified to provide a therapeutic intervention to said subject for a disease, to treat said subject for said disease, or to monitor said subject for a progression or regression of said disease.

### Claim 63

(canceled)

### Claim 64 (depends on 62)

The method of claim 62, wherein said subject is treated by administering a chemotherapy or immunotherapy to said subject.

### Claim 65

(canceled)

### Claim 66

A method for processing a plurality of nucleic acid molecules derived from a cell-free biological sample of a subject, comprising (a) bringing said plurality of nucleic acid molecules or derivatives thereof in contact with a plurality of binding agents, to provide a first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents and a second subset of said plurality of nucleic acid molecules; (b) separating said first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents from said second subset of said plurality of nucleic acid molecules; (c) subsequent to (b) circularizing nucleic acid molecules derived from said first subset of said plurality of nucleic acid molecules to obtain a first subset of circularized nucleic acid molecules; (d) subsequent to (b) circularizing nucleic acid molecules derived from said second subset of said plurality of nucleic acid molecules to obtain a second subset of circularized nucleic acid molecules; (e) sequencing said first subset of circularized nucleic acid molecules or derivatives thereof to obtain a first size and said second subset of circularized nucleic acid molecules or derivatives thereof to obtain a second size; (f) compare said first size with said second size to determine a disease level of said subject.

### Claim 67

A method for processing a plurality of nucleic acid molecules derived from a cell-free biological sample of a subject, comprising (a) bringing said plurality of nucleic acid molecules or derivatives thereof in contact with a plurality of binding agents, to provide a first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents and a second subset of said plurality of nucleic acid molecules; (b) separating said first subset of said plurality of nucleic acid molecules coupled to said plurality of binding agents from said second subset of said plurality of nucleic acid molecules; (c) subsequent to (b) circularizing nucleic acid molecules derived from said first subset of said plurality of nucleic acid molecules to obtain a first subset of circularized nucleic acid molecules; (d) subsequent to (b) circularizing nucleic acid molecules derived from said second subset of said plurality of nucleic acid molecules to obtain a second subset of circularized nucleic acid molecules; (e) sequencing said first subset of circularized nucleic acid molecules or derivatives thereof to obtain a first end sequence and said second subset of circularized nucleic acid molecules or derivatives thereof to obtain a second end sequence; (f) compare said first end sequence with said second end sequence to determine a disease level of said subject.
